RSM US LLP’s Post

In today's challenging deal environment, some #medtech companies are taking a solo path—launching their first medical devices independently, without traditional licensing or M&A. The challenge? Navigating complex regulatory pathways with limited experience. The solution? Partnering with high-quality contract development and manufacturing organizations (CDMOs). CDMOs provide expertise, specialized resources and advanced manufacturing capabilities to streamline the approval process and accelerate time to market. With cutting-edge technology and regulatory insights, they help mitigate risks and set companies up for successful launches. Learn more in our latest industry outlook: https://rsm.us/3VInsV4

  • A digital graphic for RSM features the title "Medtech outlook" in bold white text on a green background. Below, in large white letters on a blue background, it says, "Successful solo launches require CDMO support and more." The image includes a medical monitor showing heart rate lines in the background, with surgeons blurred in the operating room. RSM's logo is positioned in the top right corner, and green geometric shapes appear at the bottom.

"Exploring independent launches in the #medtech space is a bold move, but having the right partners—like experienced CDMOs—can make all the difference. 

Like
Reply

To view or add a comment, sign in

Explore topics